Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Companyâ€™s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	152M 132M 123M 113M 213M 14.47B 217M 1.45B 569M 7.22B 570M 558M 23.81B	P/E 2027 *	-	P/E 2028 *	-
Enterprise Value	129M 112M 104M 95.87M 181M 12.27B 184M 1.23B 482M 6.12B 483M 473M 20.18B	EV / Sales 2027 *	-	EV / Sales 2028 *	-
Free-Float	98.57%	Yield 2027 *	-	Yield 2028 *	-

17/06	Assertio Holdings Completes Merger With Zydus Lifesciences	MT
17/06	Assertio Holdings, Inc. Announces Board and Committee Changes, Effective June 16, 2026	CI
16/06	Assertio Holdings, Inc.(NasdaqCM:ASRT) dropped from S&P TMI Index	CI
16/06	Assertio Holdings, Inc.(NasdaqGM:ASRT) dropped from NASDAQ Composite Index	CI
16/06	Zydus Worldwide DMCC completed the acquisition of Assertio Holdings, Inc..	CI
14/05	Garda Therapeutics, Inc. cancelled the acquisition of Assertio Holdings, Inc..	CI
14/05	Zydus Worldwide DMCC entered into definitive agreement to acquire Assertio Holdings, Inc. for approximately $160 million.	CI
13/05	Assertio to be acquired by Zydus Worldwide DMCC for $23.50 per share in cash	RE
13/05	Assertio Board Approves $23.50-Per-Share Sale to Zydus Worldwide DMCC	MT
13/05	Zydus to Acquire Assertio for $166.4 Million	DJ
09/05	Assertio Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
08/05	Assertio and Garda mutually agree to delay launch of tender offer	RE
05/05	Assertio and Garda mutually agree to postpone commencement of tender offer	RE

09/04	HC Wainwright Downgrades Assertio Holdings to Neutral From Buy, Adjusts Price Target to $18 From $35	MT
03/07/24	HC Wainwright Initiates Assertio Holdings at Buy With $4 Price Target	MT
13/03/24	Lake Street Adjusts Assertio Therapeutics' Price Target to $3 From $4, Maintains Buy Rating	MT
11/05/23	BWS Financial Adjusts Assertio Therapeutics' Price Target to $10 From $8, Keeps Buy Rating	MT
11/05/23	Lake Street Adjusts Assertio Therapeutics' Price Target to $9 From $8, Keeps Buy Rating	MT

17/06	Assertio Announces Completion of Merger with Zydus Lifesciences and Fundamental Change and Make-Whole Fundamental Change Relating to its Outstanding 6.50% Convertible Senior Notes due 2027	BU
20/05	Assertio Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Assertio Holdings, Inc. - ASRT	BU
13/05	Assertio to Be Acquired by Zydus Worldwide DMCC for $23.50 Per Share in Cash	BU
08/05	Assertio and Garda Mutually Agree to Delay Launch of Tender Offer	BU
05/05	Assertio and Garda Mutually Agree to Postpone Commencement of Tender Offer	BU

Director	Title	Age	Since
Ravi Yadavar BRD	Director/Board Member	26	16/06/2026
Punit Patel BRD	Director/Board Member	-	16/06/2026

Depomed Inc Stock Nasdaq

Stocks

US2499081048

Pharmaceuticals

Valuation: Depomed Inc

Latest news : Depomed Inc

Last Transcript: Depomed Inc

Analysts' recommendations: Depomed Inc

Press Releases: Depomed Inc

Quotes and Performance

Managers and Directors: Depomed Inc

Other Pharmaceuticals

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DEPOMED INC	-9.45%	+3.54%	-	-	152M
ELI LILLY AND COMPANY	-2.39%	-6.24%	+47.10%	+146.73%	1,024B
JOHNSON & JOHNSON	-0.76%	-3.41%	+52.04%	+49.73%	618B
ABBVIE INC.	-2.33%	-5.50%	+25.55%	+64.08%	443B
ROCHE HOLDING AG	+0.68%	+0.25%	+38.47%	+31.95%	349B
NOVARTIS AG	-1.66%	-1.89%	+32.18%	+37.17%	297B
ASTRAZENECA PLC	-8.96%	-9.23%	+3.57%	+3.64%	264B
NOVO NORDISK A/S	-1.37%	-5.71%	-2.10%	-44.43%	209B
AMGEN INC.	-1.63%	+0.75%	+27.62%	+64.43%	208B
GILEAD SCIENCES, INC.	+0.72%	+1.42%	+15.88%	+73.30%	162B
Average	-2.81%	-1.35%	+26.70%	+47.40%	397.08B
Weighted average by Cap.	-1.96%	-2.17%	+34.56%	+69.56%

	2027 *	2028 *
Net sales	-	-
Net income	400K 348K 325K 298K 562K 38.13M 572K 3.83M 1.5M 19.01M 1.5M 1.47M 62.71M	-
Net Debt	-	-